The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition

Journal of Managed Care Pharmacy

Volumn 13, Issue 8 SUPPL. B, 2007, Pages

  Atlas, Steven A ^a,b,c  

^a Mount Sinai School of Medicine ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors; Angiotensin II, renin; Angiotensin receptor blockers; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; RENIN; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CATALYSIS; COUGHING; DISEASE MODEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOCRINE SYSTEM; HEART FAILURE; HORMONE RELEASE; HUMAN; HYDROLYSIS; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INHIBITION KINETICS; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER TOXICITY; MEMBRANOUS GLOMERULONEPHRITIS; METABOLITE; MONOTHERAPY; MORBIDITY; MORTALITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEINURIA; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SIDE EFFECT; TASTE DISORDER;

EID: 36248931664     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s8-b.9     Document Type: Review

References (61)

1. Piepho RW, Beal J. An overview of antihypertensive therapy in the 20th century. J Clin Pharmacol. 2000;40:967-77.
2. Ferrario CM. Role of angiotensin II in cardiovascular disease - therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7:3-14.
3. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957;106:439-53.
4. Sealey JE, Laragh JH. Renin-angiotensin-aldosterone system and the renal regulation of sodium, potassium, and pressure homeostasis. In: Windhager EE, ed. Handbook of Physiology-Section 8: Renal Physiology. Vol II. New York: Oxford University Press; 1992:1409-541.
5. Brown MJ. Direct renin inhibition - a new way of targeting the renin system. J Renin Angiotensin Aldosterone Syst. 2006;7(suppl 2):S7-S11.
6. Morgan L, Broughton PF, Kalsheker N. Angiotensinogen: molecular biology, biochemistry and physiology. Int J Biochem Cell Biol. 1996;28:1211-22.
7. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-71.
8. Reudelhuber TL. The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Curr Opin Nephrol Hypertens. 2005; 14:155-59.
9. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs. 2003;3:389-94.
10. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-27.
11. Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114:1128-35.
12. Funder JW. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J. 2002;144:S8-11.
13. Phillips MI. Tissue renin-angiotensin systems. In: Izzo JL, Black HR, ed. Hypertension Primer: The Essentials of High Blood Pressure. 2nd ed. Baltimore, MD: Lippincott William & Wilkins; 1999:23-24.
14. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999;33:1399-405.
15. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-92.
16. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-90.
17. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-27.
18. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther. 2005;19:77-87.
19. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747-803.
20. Danser AH, van Kats JP, Admiraal PJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension. 1994;24:37-48.
21. van Kats JP, Chai W, Duncker DJ, Schalekamp MADH, Danser AHJ. Adrenal angiotensin: origin and site of generation. Am J Hypertens. 2005;18:1104-10.
22. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001;14:186-94.
23. Schmidt RJ, Soman SS. Renovascular Hypertension. Available at: http://www.eMedicine.com. Accessed May 3, 2007.
24. Corvol P, Pinet F, Plouin PF, Bruneval P, Menard J. Renin-secreting tumors. Endocrinol Metab Clin North Am. 1994;23:255-70.
25. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368:1449-56.
26. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001;14:296-304.
27. Blumenfeld JD, Sealey JE, Mann SJ, et al. β-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999;12:451-59.
28. Atlas SA, Sealey JE, Laragh JH, Moon C. Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure. Lancet. 1977; 2:785-89.
29. Hollifield JW, Sherman K, Zwagg RV, Shand DG. Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension. N Engl J Med. 1976;295:68-73.
30. Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis. 2004;47:116-30.
31. Brown B, Hall AS. Renin-angiotensin system modulation: the weight of evidence. Am J Hypertens. 2005;18(9 pt 2):127S-33S.
32. Lopez-Sendon J, Swedberg K, McMurray J, et al., for the Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J. 2004;25:1454-70.
33. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-49.
34. Atlas SA, Case DB, Yu ZY, Laragh JH. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors: possible differences between enalapril and captopril. Am J Med. 1984;77:13-17.
35. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-45.
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the collaborative study group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-62.
37. Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens. 2006;20:101-08.
38. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
39. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91.
40. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
41. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-22.
42. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-85.
43. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
44. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-28.
45. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease [EUROPA] Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-88.
46. Yusuf S, Sleight P, Pogue J, et al., for The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53.
47. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-16.
48. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291-96.
49. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-68.
50. Ruilope LM, Rosei EA, Bakris GL, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005;14:196-209.
51. Hernandez-Hernandez R, Sosa-Canache B, Velasco M, Armas-Hernandez MJ, Armas-Padilla MC, Cammarata R. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens. 2002;16(suppl 1):S93-S99.
52. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol. 2001;37:440-44.
53. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905-10.
54. 1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens. 2002;15:1087-91.
55. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
56. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
57. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-69.
58. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66.
59. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414-21.
60. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-60.
61. Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm. 2007;13(8)(suppl b):S21-S33.